Proteasomal activity decreases with ApoE4 expression. by Nathan R. Zuniga (20422428)

Macrophage-specific IGF-1 overexpression decreases plaque MMP8 and. by Patricia Snarski (22305205)

Subjects:

Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

Conditional ablation of <i>Ybx1</i> leads to a reduction in cortical progenitor cell pool and a decrease in cortical thickness. by Jian Zhang (1682)

Effects of GJE extract treatment decreased accumulation of Col1a1. by Natnicha Suttawong (22367172)

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…Bar graphs depicted EVO increased mRNA expression of (D) SM22α and decreased (E) RUNX2 in CER treated P_i-induced VSMCs. …”

Repetitive stress induces a decrease in sound-evoked activity. by Ghattas Bisharat (20706928)

“…These mice exhibited a minimal change in noise-evoked PPy activity when comparing the first and second week of imaging (2-way ANOVA, F = 1.79, <i>p</i> = 0.11, post hoc baseline w1 50 dB: baseline w2 50 dB <i>p</i> = 1 Bonferroni corrected, nested ANOVA (mouse nested within session) F = 1.76, <i>p</i> = 0.12, mean ± SE). …”

Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P_i‐induced VSMCs. …”

Cases and ICU admissions throughout the pandemic. by Sixten Melander (22521804)

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

Subjects:

The parameters of gas exchange markedly decreased in maize <i>zmstomagen1/2</i> mutant compared with in wild type (WT). by Juan-Juan Xu (18590868)

Intact <i>vs.</i> damaged HSV-1 virions. by Camilla Albano (16446679)

Subjects:

HSV-1 increases <i>de novo</i> lipogenesis. by Camilla Albano (16446679)

Subjects:

IKK KO in microglia leads to increased accumulation of PK-resistant PrP <i>in vitro</i> but decreased accumulation <i>in vivo.</i> by Arielle J. D. Hay (15456341)